CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?

Key Takeaways CorMedix's shares fell 27% in 3 months after issuing a cautious 2026 outlook for DefenCath.CRMD expects 2026 revenues of $300-$320M, with DefenCath sales weighted to early 2026.CorMedix acquired Melinta, adding seven therapies to diversify its commercial portfolio beyond DefenCath.Shares of CorMedix (CRMD) have witnessed a sharp decline over the past three months. A key reason for the stocks’ decline during this time has been the company’s bearish 2026 financial outlook. In January, management ...